Secukinumab（抗il -17）诱导早期诊断的1型糖尿病临床退化：1例报告

IF 4.6 2区医学 Q1 ENDOCRINOLOGY & METABOLISM

Diabetes & metabolism Pub Date : 2025-04-04 DOI:10.1016/j.diabet.2025.101643

Blanca Gómez-Zaragoza , María Ruiz-Rodríguez , Pablo Rodríguez de Vera Gómez , Daniela Decan-Bardasz , María Asunción Martínez-Brocca

{"title":"Secukinumab（抗il -17）诱导早期诊断的1型糖尿病临床退化：1例报告","authors":"Blanca Gómez-Zaragoza , María Ruiz-Rodríguez , Pablo Rodríguez de Vera Gómez , Daniela Decan-Bardasz , María Asunción Martínez-Brocca","doi":"10.1016/j.diabet.2025.101643","DOIUrl":null,"url":null,"abstract":"<div><div>We report the case of a 30-year-old male with psoriatic arthritis treated with secukinumab (anti-IL-17A) who developed new-onset type 1 diabetes mellitus (T1DM). During follow-up, a consistent reduction in insulin requirements and glycemic variability was observed in the two weeks following each dose of secukinumab. This suggests a possible immunomodulatory effect of IL-17 inhibition on beta-cell function and glycemic control. To our knowledge, this is the first report describing clinical benefits of secukinumab in the early stages of T1DM, highlighting its potential as a therapeutic tool in modulating autoimmune processes involved in disease progression.</div></div>","PeriodicalId":11334,"journal":{"name":"Diabetes & metabolism","volume":"51 3","pages":"Article 101643"},"PeriodicalIF":4.6000,"publicationDate":"2025-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Secukinumab (Anti-IL-17) induces clinical regression in early diagnosed type 1 diabetes: A case report\",\"authors\":\"Blanca Gómez-Zaragoza , María Ruiz-Rodríguez , Pablo Rodríguez de Vera Gómez , Daniela Decan-Bardasz , María Asunción Martínez-Brocca\",\"doi\":\"10.1016/j.diabet.2025.101643\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><div>We report the case of a 30-year-old male with psoriatic arthritis treated with secukinumab (anti-IL-17A) who developed new-onset type 1 diabetes mellitus (T1DM). During follow-up, a consistent reduction in insulin requirements and glycemic variability was observed in the two weeks following each dose of secukinumab. This suggests a possible immunomodulatory effect of IL-17 inhibition on beta-cell function and glycemic control. To our knowledge, this is the first report describing clinical benefits of secukinumab in the early stages of T1DM, highlighting its potential as a therapeutic tool in modulating autoimmune processes involved in disease progression.</div></div>\",\"PeriodicalId\":11334,\"journal\":{\"name\":\"Diabetes & metabolism\",\"volume\":\"51 3\",\"pages\":\"Article 101643\"},\"PeriodicalIF\":4.6000,\"publicationDate\":\"2025-04-04\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Diabetes & metabolism\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1262363625000382\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ENDOCRINOLOGY & METABOLISM\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Diabetes & metabolism","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1262363625000382","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 0

摘要

我们报告一例30岁男性银屑病关节炎患者，接受secukinumab（抗il - 17a）治疗，并发新发1型糖尿病（T1DM）。在随访期间，在每次给药后的两周内观察到胰岛素需求和血糖变异性的持续降低。这表明IL-17抑制可能对β细胞功能和血糖控制有免疫调节作用。据我们所知，这是第一份描述secukinumab在T1DM早期临床获益的报告，强调了其作为调节自身免疫过程参与疾病进展的治疗工具的潜力。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Secukinumab (Anti-IL-17) induces clinical regression in early diagnosed type 1 diabetes: A case report

We report the case of a 30-year-old male with psoriatic arthritis treated with secukinumab (anti-IL-17A) who developed new-onset type 1 diabetes mellitus (T1DM). During follow-up, a consistent reduction in insulin requirements and glycemic variability was observed in the two weeks following each dose of secukinumab. This suggests a possible immunomodulatory effect of IL-17 inhibition on beta-cell function and glycemic control. To our knowledge, this is the first report describing clinical benefits of secukinumab in the early stages of T1DM, highlighting its potential as a therapeutic tool in modulating autoimmune processes involved in disease progression.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Diabetes & metabolism 医学-内分泌学与代谢

CiteScore

12.00

自引率

4.20%

发文量

审稿时长

13 days

期刊介绍： A high quality scientific journal with an international readership Official publication of the SFD, Diabetes & Metabolism, publishes high-quality papers by leading teams, forming a close link between hospital and research units. Diabetes & Metabolism is published in English language and is indexed in all major databases with its impact factor constantly progressing. Diabetes & Metabolism contains original articles, short reports and comprehensive reviews.